GSK in talks to acquire US oncology biotech Nuvalent for more than $9 billion in largest deal in over a decade
GSK, the UK pharmaceutical group, is in discussions to acquire Nuvalent, a US oncology biotech, in a deal that sources value at between $9 billion and $10 billion. If completed, it would represent a premium of roughly 29% to 43% over Nuvalent's market capitalisation of nearly $7 billion at Monday's close, and would be the second largest acquisition in GSK's history — trailing only its 2014 asset swap with Novartis, in which it assumed control of the Swiss drugmaker's vaccines division in a transaction valued at $20 billion. The two companies have been in discussions with the aim of finalising a deal as early as this week, though both sides have yet to reach a final agreement and talks could still fall apart over last-minute hurdles. No advisers have been named publicly. The strategic logic centres on Nuvalent's pipeline of targeted cancer therapies. Its lead asset, neladalkib, a therapy targeting certain types of lung cancer, is currently under FDA review with a deadline of 27 November. The company also has a new drug application for zidesamtinib, for patients with ROS1-positive non-small cell lung cancer, also under FDA review. Analysts have estimated combined annual revenues of around $823 million for the two drugs in the 2029 financial year. The move marks a notable departure from the stated strategy of new GSK chief executive Luke Miels, who told investors in February that he would focus on transactions in the £2 billion to £4 billion range. GSK's share price has climbed roughly 29% since Miels' appointment as CEO-designate was announced in September, reflecting investor optimism about the company's direction under its new leadership.
Why this matters
A deal at this scale would activate substantial public M&A advisory mandates spanning corporate, regulatory, and life sciences practices on both sides of the Atlantic. The primary legal work involves negotiating and executing a cross-border SPA (share purchase agreement), co-ordinating FDA and potentially FTC (Federal Trade Commission) antitrust clearances in the US, and assessing whether the deal triggers any UK regulatory review. For a UK-listed acquirer buying a Nasdaq-listed biotech, advisers must also navigate dual market disclosure obligations and shareholder approval thresholds. The biotech dealmaking cycle — buoyed by pipeline risk reduction and pre-commercialisation acquisitions — has been running hot in 2026, and GSK's willingness to move beyond its previously stated £2–4 billion comfort zone is a signal that pharma majors are competing aggressively for late-stage oncology assets. The 29–43% premium range reflects standard biotech acquisition pricing and will require robust fairness opinion work.
On the Ground
On this type of cross-border public M&A deal, a trainee would manage the conditions precedent (CP) checklist — tracking regulatory filings in each jurisdiction, Board approvals, and shareholder notification requirements. Drafting and verifying SPA schedules, indexing the due diligence report, and maintaining the completion bible would be central tasks.
Interview prep
Soundbite
A $9bn pharma deal signals PE-era premiums are now baseline for late-stage oncology assets.
Question you might get
“What regulatory approvals would GSK's proposed acquisition of a Nasdaq-listed US biotech require, and which might be the most contentious to obtain?”
Full answer
GSK is in talks to acquire US oncology biotech Nuvalent for between $9 billion and $10 billion, which would be its largest acquisition in over a decade. For law firms, a deal of this size generates substantial cross-border M&A advisory work — corporate, antitrust, and regulatory practices all activate simultaneously. It reflects the broader 2026 biotech dealmaking wave, where large pharma groups are front-loading pipeline risk by acquiring pre-commercialisation assets before FDA approval materialises. The premium of up to 43% over market cap is characteristic of pipeline acquisitions where the buyer is pricing in regulatory success and future revenue, which in turn raises the stakes on deal certainty mechanics and material adverse change clauses. This suggests pharma M&A deal volumes will remain elevated through the second half of the year as companies race to secure late-stage assets.
Sources
My notes
saved